Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96G04

UPID:
EF2KT_HUMAN

ALTERNATIVE NAMES:
eEF2-lysine methyltransferase

ALTERNATIVE UPACC:
Q96G04; D3DUF0; Q96S85

BACKGROUND:
The enzyme Protein-lysine N-methyltransferase EEF2KMT, alternatively named eEF2-lysine methyltransferase, is integral to the process of protein synthesis. It specifically catalyzes the trimethylation of the elongation factor EEF2, a modification necessary for the proper functioning of this factor during protein elongation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions and mechanisms of Protein-lysine N-methyltransferase EEF2KMT holds significant promise for the development of novel therapeutic approaches. Given its essential role in the synthesis of proteins, targeting this enzyme could lead to breakthroughs in treating conditions associated with protein synthesis abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.